-
Roche and Genentech’s Lunsumio-Polivy shows promise in Phase III trial
23 Jun 2025 12:47 GMT
… compared the combination to MabThera/Rituxan (rituximab), … profiles of the individual trial medicines.
Lunsumio and Polivy … bispecific antibody and antibody-drug conjugate, which could … content on Pharmaceutical Technology (or Clinical Trials Arena) is …
-
Mixed outcomes for pharma in big week for FDA adcomms
22 May 2025 11:49 GMT
… the phase 3 AQUILA trial of the drug, which showed a progression … the New England Journal of Medicine.
HR-SMM is a … months without any active treatment. If the FDA approves Darzalex Faspro for … 's anti-CD20 antibody MabThera/Rituxan (rituximab) plus …
-
FDA Panel Votes Against Columvi-GemOx sBLA for R/R DLBCL Over Regional Data Concerns from STARGLO Trial
21 May 2025 23:06 GMT
… STARGLO trial (NCT04408638), the FDA’s Oncologic Drugs Advisory Committee … PhD, Roche chief medical officer and head of … trial compared the efficacy and safety of Columvi plus GemOx versus MabThera … effective, readily available treatment options and the …
-
Roche provides update on US FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory DLBCL
22 May 2025 06:32 GMT
… US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee ( … randomised, multiregional clinical trial, supporting its recent … with other medicines for the treatment of diffuse … Polivy (polatuzumab vedotin) and MabThera/Rituxan (rituximab), …
-
EU Approves Roche’s Columvi as First Bispecific Antibody for DLBCL After Initial Treatment
16 Apr 2025 16:40 GMT
… overall survival (OS) improvement versus MabThera/Rituxan (rituximab) and GemOx … treatment advances have been made, challenges with the accessibility of existing medicines … offers an ‘’off-the-shelf’’ treatment regimen, readily available for infusion …
-
Approval moves Columvi earlier in DLBCL treatment pathway
14 Apr 2025 12:25 GMT
… 's anti-CD20 antibody MabThera/Rituxan (rituximab) plus chemo … cell transplant (ASCT). The US FDA is due to make a … running the Epcore DLBCL-4 trial, which is testing Epkinly plus … is that its drug uses a fixed duration of treatment, while AbbVie …
-
EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia
04 Mar 2025 00:07 GMT
… positive opinion by the European Medicines Agency (EMA)’s Committee … Jaypirca was one of 16 drugs for which CHMP extended therapeutic … in a randomized Phase III trial in this patient population, … , for treatment of not only CLL but also rheumatoid arthritis, in …
-
EMA human medicine committee recommends approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
03 Mar 2025 20:16 GMT
… with Polivy (polatuzumab vedotin) and MabThera/Rituxan, cyclophosphamide, doxorubicin and … gemcitabine plus oxaliplatin (GemOx) versus MabThera/Rituxan (rituximab) in combination … in combination with other medicines for the treatment of diffuse large B …
-
Brentuximab Vedotin Plus Lenalidomide and Rituximab Receives FDA Approval for Adults With LBCL
12 Feb 2025 17:51 GMT
… a rituximab (Rituxan, Mabthera; Genentech, Roche) product … is a prescription medicine that is … Trial
Trial Name: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment … .fda.gov/drugs/;resources-information-approved-drugs/fda-approves …
-
Rituxan Hycela & MabThera (Rituximab) Market Outlook 2025-2034: Size, Trends & Competitive Landscape
29 Jan 2025 17:41 GMT
… Rituxan Mabthera?
The rituxan hycela, rituxan mabthera rituximab … focus on patient-centric treatment options, and geographic … US Food and Drug Administration FDA approval for RIABNI … Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications
Where …